The Complete Cellular Energy Peptide Protocol

Your mitochondria are not just power plants. They are dynamic organelles that constantly shift their structure, their efficiency, and their output based on the signals they receive, and almost every intervention in this protocol is trying to speak to a different part of that system.

The full chain looks like this. Your mitochondria produce energy through a process called oxidative phosphorylation, which is where electrons move through a series of proteins in the inner mitochondrial membrane and that movement drives the production of ATP, the molecule your cells actually use to do work. For that system to run, you need raw materials coming in, you need the membrane itself to be intact and structurally organized, you need the enzymes that manage energy sensing to be active, and you need the cell population to be free of enough senescent cells that you are not drowning in inflammatory signaling that disrupts the whole operation. Every tier in this protocol is addressing one of those four things.

Tier one is the raw material problem. Creatine phosphate is what your cells use to regenerate ATP in between the slower output from oxidative phosphorylation, so 5 grams per day is keeping that buffer full. CoQ10 is a molecule that physically carries electrons between the protein complexes in the membrane, and without enough of it the whole chain slows down. Magnesium is required as a cofactor for over 300 enzymatic reactions including the ones that synthesize ATP directly. Zinc, D3, K2, and fish oil are supporting the broader hormonal and inflammatory environment that determines how well the mitochondria respond to the signals they receive. None of this is exotic. It is the floor, and you build everything else on top of it.

Tier two is the NAD+ problem. NAD+ is something called a coenzyme, which is a small molecule that enzymes need to do their job, and in the context of mitochondria it is the molecule that accepts electrons from the food you eat and carries them to the electron transport chain. The problem is that NAD+ levels fall with age, and they fall because the enzymes that consume NAD+ for DNA repair and stress response continue to be active while the enzyme that makes NAD+ in the first place, something called NAMPT, becomes less productive over time. By around age 50, tissue NAD+ levels may be less than half of what they were at 20.

Injectable NAD+ at 50 to 100 milligrams subcutaneous three to five times per week bypasses the conversion steps that oral precursors have to go through, which is why it is included here rather than just recommending NMN or niacin at every age. The cycling recommendation, 8 to 12 weeks on and 4 to 8 weeks off, exists because long-term exogenous NAD+ supply can actually reduce NAMPT activity, the same enzyme you are trying to support, so you use the external supply to fill the gap while protecting your endogenous machinery.

Tier three is the senescent cell problem, and this is where the biology gets more consequential as you get older. Senescent cells are cells that have stopped dividing but have not died. They accumulate over decades, and they secrete a chronic low-grade inflammatory signal that disrupts tissue function around them, including the mitochondrial dynamics in neighboring healthy cells. Past 45 or 50, the burden of these cells becomes high enough that it acts as a bottleneck. You can optimize every other part of the system and still not see the output you expect because the environment those mitochondria are sitting in is chronically inflamed.

FOXO4-DRI is a peptide that works by targeting a survival signal that senescent cells use to avoid apoptosis, which is the normal programmed cell death process. Healthy cells do not rely on this signal in the same way, which is what creates selectivity. In preclinical mouse studies, FOXO4-DRI showed 11.73-fold selectivity for senescent cells over normal cells, and it is important to be clear that this is still preclinical data and no large human trials have been completed. Epithalon appears to work through a different mechanism, activating an enzyme called telomerase that helps maintain the protective caps on chromosomes, and the evidence here is also early, coming primarily from animal models and small human studies.

The dosing schedule for both, once or twice a year rather than continuous use, reflects the goal of periodic clearance rather than constant intervention, because the senolytic effect you are looking for does not require ongoing administration.

Tier four is the membrane repair and energy efficiency problem, and this is where SS-31 and MOTS-c come in as the core of the stack.

SS-31, also called elamipretide, works by binding to something called cardiolipin, which is a specialized phospholipid that exists almost exclusively in the inner mitochondrial membrane and that is required for the electron transport chain proteins to hold their correct structure. When cardiolipin is damaged or poorly organized, the protein complexes responsible for moving electrons lose their arrangement, electrons leak out early, and instead of producing ATP that energy is lost as reactive oxygen species that damage the membrane further. SS-31 binds to cardiolipin, stabilizes the membrane architecture, and in doing so reduces ROS production by 40 to 60 percent in cellular and animal models. In the TAZ-POWER trial, which involved patients with a genetic cardiolipin deficiency called Barth syndrome, three years of SS-31 treatment produced a 96-meter improvement on the six-minute walk test and a 45 percent improvement in leg strength and cardiac function. That is a clinical population with severe baseline dysfunction, but the mechanism is the same membrane stabilization that matters in aging tissue.

MOTS-c works through a completely different pathway. It is a peptide encoded within the mitochondrial genome itself, which makes it unusual, and it activates something called AMPK, which is an enzyme that functions like an energy sensor in the cell. When AMPK is active, the cell shifts toward more efficient energy use, improves insulin sensitivity, increases glucose uptake into muscle, and reduces the oxidative stress that causes the cardiolipin damage that SS-31 is repairing. The two peptides are not redundant. One is fixing the structure and the other is improving how the cell signals around that structure, which is why they can be run together.

Tier five is the correction layer, and the key word is correction. 5-Amino-1MQ blocks an enzyme called NNMT, which is overactive in adipose tissue in people with excess body fat and which diverts the raw material that would otherwise become NAD+ into a metabolic dead end. In mice with diet-induced obesity, NNMT inhibition produced a 35 percent reduction in body mass. But if there is no excess adipose tissue, there is no excess NNMT activity to block and no dysfunction to correct. The same logic applies to methylene blue, which can donate electrons directly to the electron transport chain and bypass damaged segments, but which carries real risks in people with G6PD deficiency or who are on serotonergic medications.

The broader principle underneath all of this is that cellular energy systems fail in layers. The membrane degrades, the NAD+ pool depletes, senescent cells accumulate and inflame the environment, and the signaling enzymes that would otherwise compensate lose their sensitivity. No single intervention addresses all of those layers, and no amount of optimization at the membrane level is going to overcome a cell population that is spending most of its energy managing chronic inflammatory signals from its neighbors.

That is not a reason to do everything at once. It is a reason to understand which layer is actually your bottleneck.

---

References

1. Thompson WR et al. TAZ-POWER trial. Genetics in Medicine. 2024;26(7):101133 — SS-31 (elamipretide) +96m on 6MWT, +45% leg strength/cardiac function over 3 years
2. Szeto HH. Mitochondria-targeted cytoprotective peptides. British Journal of Pharmacology. 2014;171:2029-2050 — SS-31 mechanism, cardiolipin binding, 40-60% ROS reduction
3. Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism. 2015 — MOTS-c AMPK activation, insulin sensitivity
4. Gudiksen A et al. Free Radical Biology and Medicine. 2026;246:682-696 — MOTS-c improves intrinsic mitochondrial efficiency
5. de Keizer et al. Targeted apoptosis of senescent cells. Cell. 2017 — FOXO4-DRI senolytic mechanism, 11.73-fold selectivity
6. Khavinson et al. Epithalon telomerase activation research — limited human + animal data
7. Nkandeu et al. 5-Amino-1MQ mouse study — 35% body mass reduction, NNMT inhibition in adipose tissue

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness